M&A analysis: bolt-ons for J&J and Bristol
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
The month ahead: September’s upcoming events
It’s a new term for biotech and its investors.
A subcutaneous answer to PD-1’s patent problem
PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst.
